Base de dados : LILACS
Pesquisa : D10.477 [Categoria DeCS]
Referências encontradas : 11 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2 ir para página        

  1 / 11 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
ALVES, Sydney Hartz
Texto completo
Id: biblio-828164
Autor: Kubiça, Thaís Felli; Denardi, Laura Bedin; Azevedo, Maria Isabel; Oliveira, Vanessa; Severo, Luiz Carlos; Santurio, Janio Morais; Alves, Sydney Hartz.
Título: Antifungal activities of tacrolimus in combination with antifungal agents against fluconazole-susceptible and fluconazole-resistant Trichosporon asahii isolates
Fonte: Braz. j. infect. dis;20(6):539-545, Nov.-Dec. 2016. tab.
Idioma: en.
Projeto: FAPERGS; . CNPq.
Resumo: ABSTRACT The antifungal activity of tacrolimus in combination with antifungal agents against different fungal species has been previously reported. Here we report the in vitro interactions between tacrolimus and amphotericin B, fluconazole, itraconazole, and caspofungin against 30 clinical isolates of both fluconazole-susceptible and fluconazole-resistant Trichosporon asahii. For these analyses, we used the broth microdilution method based on the M27-A3 technique and checkerboard microdilution method. Tacrolimus showed no activity against T. asahii strains (minimal inhibitory concentrations, MICs > 64.0 µg mL−1). However, a larger synergistic interaction was observed by the combinations tacrolimus + amphotericin B (96.67%) and tacrolimus + caspofungin (73.33%) against fluconazole-susceptible isolates. Combinations with azole antifungal agents resulted in low rates of synergism for this group (fluconazole + tacrolimus = 40% and itraconazole + tacrolimus = 10%). Antagonistic interactions were not observed. For the fluconazole-resistant T. asahii group, all tested combinations showed indifferent interactions. The synergism showed against fluconazole-susceptible T. asahii isolates suggests that the potential antifungal activity of tacrolimus deserves in vivo experimental investigation, notably, the combination of tacrolimus with amphotericin B or caspofungin.
Descritores: Trichosporon/efeitos dos fármacos
Tacrolimo/farmacologia
Inibidores de Calcineurina/farmacologia
Antifúngicos/farmacologia
-Testes de Sensibilidade Microbiana
Fluconazol/farmacologia
Anfotericina B/farmacologia
Itraconazol/farmacologia
Interações Medicamentosas
Sinergismo Farmacológico
Equinocandinas/farmacologia
Lipopeptídeos/farmacologia
Caspofungina
Limites: Humanos
Responsável: BR1.1 - BIREME


  2 / 11 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-888105
Autor: Danielescu, Ciprian; Cantemir, Alina; Chiselita, Dorin.
Título: Successful treatment of fungal endophthalmitis using intravitreal caspofungin / O primeiro relato de caspofungina intravítrea no tratamento de endoftalmite fúngica
Fonte: Arq. bras. oftalmol;80(3):196-198, May-June 2017. graf.
Idioma: en.
Resumo: ABSTRACT Fungal endophthalmitis is a rare condition often associated with poor prognosis. We present a case of postoperative acute fungal endophthalmitis caused by the yeast-like fungus Stephanoascus ciferrii (Candida ciferrii). The fungus was resistant to fluconazole, voriconazole, and amphotericin B but susceptible to caspofungin. Because the degree of vitreal penetration of caspofungin after its intravenous administration is unclear, we performed multiple intravitreal injections, first with 50 µg/0.1 ml and then with 250 µg/0.1 ml caspofungin. Despite the recurrence of symptoms, intravitreal injection of caspofungin finally abolished the inflammation and achieved ambulatory vision that persisted until 1 year of follow-up. To our knowledge, this is the first report of S. ciferrii endophthalmitis and its successful treatment with intravitreal caspofungin.

RESUMO Endoftalmite fúngica é uma ocorrência rara, muitas vezes associada com mau prog nóstico. Apresentamos um caso de endoftalmite fúngica aguda pós-operatória causada por fungo de levedura incomum, Stephanoascus ciferrii (Candida ciferrii). O fungo foi resistente ao fluconazol, ao voriconazol e à anfotericina B e susceptível à caspofun gina. Dado que a penetração vítrea da caspofungina após administração intravenosa não é clara, optou-se por realizar múltiplas injecções intravítreas, primeiro de 50 µg e depois de 250 µg de caspofungina, e finalmente obteve-se a resolução da inflamação e a visão recuperada foi mantida por pelo menos um ano após o ocorrido. No nosso conhecimento, este é o primeiro relato de endoftalmite por Stephanoascus ciferrii e o primeiro relato de endoftalmite fúngica tratada com sucesso com caspofungina intravítrea.
Descritores: Infecções Oculares Fúngicas/tratamento farmacológico
Endoftalmite/microbiologia
Endoftalmite/tratamento farmacológico
Equinocandinas/administração & dosagem
Injeções Intravítreas
Antifúngicos/administração & dosagem
-Vitrectomia
Acuidade Visual
Reprodutibilidade dos Testes
Resultado do Tratamento
Facoemulsificação/efeitos adversos
Saccharomycetales
Lipopeptídeos/administração & dosagem
Caspofungina
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  3 / 11 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-974336
Autor: Zhao, Junfeng; Zhang, Chong; Lu, Zhaoxin.
Título: Differential proteomics research of Bacillus amyloliquefaciens and its genome-shuffled saltant for improving fengycin production
Fonte: Braz. j. microbiol;49(supl.1):166-177, 2018. tab, graf.
Idioma: en.
Projeto: National Natural Science Foundation of China.
Resumo: Abstract In the previous study, we used genome shuffling to improve fengycin production of the original strain Bacillus amyloliquefaciens ES-2-4. After two rounds of genome shuffling, a high-yield recombinant FMB72 strain that exhibited 8.30-fold increase in fengycin production was obtained. In this study, comparative proteomic analysis of the parental ES-2-4 and genome-shuffled FMB72 strains was conducted to examine the differentially expressed proteins. In the shuffled strain FMB72, 50 differently expressed spots (p < 0.05) were selected to be excised and analyzed using Matrix-Assisted Laser Desorption/Ionization Time of Flight/Time of Flight Mass Spectrometry, and finally 44 protein spots were confidently identified according to NCBI database. According to clusters of orthologous groups (COG) functional category analysis and related references, the differentially expressed proteins could be classified into several functional categories, including proteins involved in metabolism, energy generation and conversion, DNA replication, transcription, translation, ribosomal structure and biogenesis, cell motility and secretion, signal transduction mechanisms, general function prediction. Of the 44 identified proteins, signaling proteins ComA and Spo0A may positively regulate fengycin synthesis at transcriptional level. Taken together, the present study will be informative for exploring the exact roles of ComA and Spo0A in fengycin synthesis and explaining the molecular mechanism of fengycin synthesis.
Descritores: Proteínas de Bactérias/metabolismo
Lipopeptídeos/biossíntese
Bacillus amyloliquefaciens/genética
Bacillus amyloliquefaciens/metabolismo
-Proteínas de Bactérias/genética
Proteínas de Bactérias/química
Genoma Bacteriano
Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz
Embaralhamento de DNA
Proteômica
Bacillus amyloliquefaciens/química
Responsável: BR1.1 - BIREME


  4 / 11 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-828202
Autor: Jha, Sujata S; Joshi, Sanket J; S. J., Geetha.
Título: Lipopeptide production by Bacillus subtilis R1 and its possible applications
Fonte: Braz. j. microbiol;47(4):955-964, Oct.-Dec. 2016. tab, graf.
Idioma: en.
Resumo: Abstract The possible application of a bacterial strain - Bacillus subtilis R1, isolated from an oil contaminated desert site in India, as biocontrol agent and its biosurfactant in microbial enhanced oil recovery are discussed. The biosurfactant production in minimal medium was carried out at different temperatures and salt concentrations, where it produced an efficient biosurfactant at 30-45 °C and in presence of up to 7% salt. It significantly reduced the surface tension from 66 ± 1.25 mN/m to 29 ± 0.85 mN/m within 24 h. In order to enhance the biosurfactant production, random mutagenesis of B. subtilis R1 was performed using chemical mutagen - ethyl methanesulfonate. Majority of the isolated 42 mutants showed biosurfactant production, but the difference was statistically insignificant as compared with parent strain R1. Therefore none of the mutants were selected for further study, and only parent strain R1 was studied. The biosurfactant was quite stable under harsh conditions for up to 10 days. The biosurfactant was extracted and characterized as similar to the lipopeptide group - surfactins and fengycin. The crude oil displacement experiments using biosurfactant broth in sand pack glass columns showed 33 ± 1.25% additional oil recovery. The strain also showed inhibition of various plant pathogenic fungi on potato dextrose agar medium.
Descritores: Bacillus subtilis/metabolismo
Lipopeptídeos/biossíntese
-Tensoativos/metabolismo
Tensoativos/farmacologia
Bacillus subtilis/classificação
Bacillus subtilis/genética
RNA Ribossômico 16S/genética
Testes de Sensibilidade Microbiana
Mutagênese
Espectroscopia de Infravermelho com Transformada de Fourier
Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz
Lipopeptídeos/farmacologia
Engenharia Metabólica
Concentração de Íons de Hidrogênio
Antifúngicos/metabolismo
Antifúngicos/farmacologia
Responsável: BR1.1 - BIREME


  5 / 11 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-887383
Autor: Ozdemir, Abdurrahman A.
Título: Activador tisular del plasminógeno recombinante para el tratamiento de la vegetación intracardíaca en un lactante de muy bajo peso al nacer / Recombinant tissue plasminogen activator treatment for intracardiac vegetation in a very low birth weight infant
Fonte: Arch. argent. pediatr;115(5):307-310, oct. 2017. ilus.
Idioma: en; es.
Resumo: Las nuevas opciones de tratamiento prolongan la hospitalización y aumentan las infecciones intrahospitalarias bacterianas y fúngicas, pero también mejoran la sobrevida de los recién nacidos hospitalizados en la unidad de cuidados intensivos neonatales. Las infecciones fúngicas invasivas en neonatos están asociadas con una morbimortalidad significativa. También pueden diseminarse a órganos específicos y causar endocarditis, endoftalmitis, artritis séptica, nefropatía obstructiva y meningitis. En el caso de la endocarditis, se recomiendan tratamientos antimicóticos sistémicos agresivos y, en algunos casos, la intervención quirúrgica del neonato. Informamos el caso de un lactante prematuro, de bajo peso al nacer, con vegetación intracardíaca. Esta es una complicación rara y potencialmente mortal de infecciones fúngicas invasivas. El paciente recibió tratamiento con caspofungina y un activador tisular del plasminógeno recombinante, en vez de una intervención quirúrgica.

Developing treatment options have resulted in prolonged admission and increased bacterial and fungal nosocomial infections as well as improved survival in neonatal intensive care unit. Invasive fungal infections in newborns are associated with significant morbidity and mortality and can cause endorgan dissemination such as endocarditis, endophthalmitis, septic arthritis, obstructive nephropathy and meningitis. Endocarditis requires aggressive systemic antifungal therapy and sometimes surgical intervention in neonates. We report a low birth weight premature infant with intracardiac vegetation that is rare and a life-threatening complication of invasive fungal infections. He was treated with caspofungin and recombinant tissue plasminogen activator in stead of surgical intervention.
Descritores: Candidíase/tratamento farmacológico
Ativador de Plasminogênio Tecidual
Endocardite/microbiologia
Endocardite/tratamento farmacológico
Equinocandinas/uso terapêutico
Lipopeptídeos/uso terapêutico
Candida parapsilosis
Antifúngicos/uso terapêutico
-Proteínas Recombinantes/uso terapêutico
Recém-Nascido de muito Baixo Peso
FRONTAL SINUS0
Limites: Humanos
Masculino
Recém-Nascido
Tipo de Publ: Relatos de Casos
Responsável: AR94.1 - Centro de Información Pediatrica


  6 / 11 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-838238
Autor: Rosanova, María T; Bes, David; Serrano Aguilar, Pedro; Cuellar Pompa, Leticia; Sberna, Norma; Lede, Roberto.
Título: Eficacia y seguridad de la caspofungina en pediatría: revisión sistemática y metaanálisis / Efficacy and safety of caspofungin in children: systematic review and meta-analysis
Fonte: Arch. argent. pediatr;114(4):305-312, ago. 2016. graf, tab.
Idioma: en; es.
Resumo: Las infecciones fúngicas invasivas son una importante causa de morbimortalidad en pediatría. La caspofungina es una equinocandina utilizada como alternativa en la prevención y/o tratamiento de ciertas infecciones fúngicas invasivas en niños, aunque con poca evidencia sobre su eficacia y seguridad en comparación con el tratamiento habitual. Objetivos. Evaluar la eficacia y seguridad de la caspofungina comparada con otros antifúngicos en la prevención y/o tratamiento de infecciones fúngicas invasivas en pediatría. Material y métodos. La estrategia de búsqueda inicial tuvo como objetivo identificar estudios controlados aleatorizados de aceptable calidad metodológica (escala de Jadad > 3) mediante la palabra clave "caspofungin" realizados en pacientes de entre los 0 y los 18 años. Resultados. Solo 3 publicaciones cumplieron los criterios de inclusión. De ellas, 2 fueron en población pediátrica y una en neonatal. No se documentó una mayor incidencia de efectos adversos para la caspofungina y su eficacia no se diferenció de otros antifúngicos (RR típico 1,47; IC 95%: 0,78-2,79). Conclusiones. Esta revisión sistemática sugiere que la caspofungina podría considerarse como una alternativa para su indicación en pediatría en la prevención y tratamiento de las infecciones fúngicas invasivas. Sin embargo, dado el pequeño número de publicaciones existentes, se requieren más estudios para alcanzar conclusiones definitivas.

Invasive fungal infections are a significant cause of morbidity and mortality in children. Caspofungin is an echinocandin used as an alternative treatment in the prevention and/or treatment of certain invasive fungal infections in children, although compared to the standard treatment there is little evidence on its efficacy and safety. Objectives. To evaluate the efficacy and safety of caspofungin compared with other antifungal drugs for the prevention and/or treatment of invasive fungal infections in children. Material and methods. The objective of the initial search strategy was to identify randomized controlled studies of acceptable methodological quality (Jadad scale >3), through the key word "caspofungin", conducted in patients with an age range from 0 to 18 years old. Results. Only 3 publications met the inclusion criteria. Two of them were studies conducted in children and one in newborn infants. A higher incidence of adverse events was not documented for caspofungin and its efficacy was not different from that of other antifungal drugs (typical RR 1.47; CI 95%: 0.78-2.79). Conclusions. This systematic review suggests that caspofungin could be considered as an alternative drug in children for the prevention and treatment of invasive fungal infections. However, given the small number of existing publications, more studies are required to reach definite conclusions.
Descritores: Equinocandinas/uso terapêutico
Lipopeptídeos/uso terapêutico
FRONTAL SINUS0
Micoses/tratamento farmacológico
Antifúngicos/uso terapêutico
-Resultado do Tratamento
Limites: Humanos
Criança
Tipo de Publ: Revisão Sistemática
Responsável: AR94.1 - Centro de Información Pediatrica


  7 / 11 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-797151
Autor: Tótoli, Eliane Gandolpho; Salgado, Hérida Regina Nunes.
Título: A green approach for the quantification of daptomycin in pharmaceutical formulation by UV spectrophotometry
Fonte: Braz. j. pharm. sci;51(4):811-821, Oct.-Dec. 2015. ilus, tab.
Idioma: en.
Resumo: Daptomycin is the first approved drug from a new class of antimicrobials, the cyclic lipopeptides, and is a very important antimicrobial agent in current clinical practice. Currently, there are no "green" analytical methods described in the literature to analyze the typical pharmaceutical dosage form of daptomycin. Thus, the aim of this work was to validate an environment-friendly spectrophotometric method in the UV region, for the analysis of daptomycin as a lyophilized powder. Water was used as diluent and the analyses were carried out on a spectrophotometer at 221 nm. The method met all validation requirements of the ICH guidelines, over a concentration range of 6-21 µg mL-1. A Student's t-test demonstrated that the proposed method was comparable to an HPLC method previously validated. Thus, the validated spectrophotometric method could quantify daptomycin in a powder form for injectable solutions, while being an economical, rapid, and "green" alternative for routine analysis in quality control...

A daptomicina é o primeiro membro aprovado de uma nova classe de antimicrobianos, os lipopeptídeos cíclicos, e é muito importante para a prática clínica atualmente. Não existem métodos analíticos "verdes" descritos na literatura para a análise da daptomicina na forma farmacêutica. Desta forma, o objetivo deste trabalho foi a validação de método espectrofotométrico na região do UV ambientalmente favorável para análise da daptomicina em pó liofilizado. A água foi escolhida como diluente e as análises foram realizadas em 221 nm. O método atendeu a todas as exigências de validação dos guias do ICH, na faixa de 6-21 µg mL-1. Teste t de Student mostrou que o método proposto é intercambiável com método de HPLC previamente validado. Assim, o método espectrofotométrico validado é capaz de quantificar a daptomicina em pó para solução injetável e é uma opção econômica, rápida e "verde" para análises de rotina do controle de qualidade deste fármaco...
Descritores: Daptomicina/análise
Espectrofotometria Ultravioleta/métodos
-Anti-Infecciosos/análise
Lipopeptídeos
Controle de Qualidade
Limites: Humanos
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  8 / 11 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-742902
Autor: Lamari, Neuseli Marino.
Título: Effectiveness of a cardiac rehabilitation program during hospital stay / Efetividade de um programa reabilitação cardíaca durante a fase hospitalar
Fonte: Rev. bras. cir. cardiovasc = Braz. j. cardiovasc. surg. (impr.);30(1):VIII-IX, Jan-Mar/2015.
Idioma: en.
Descritores: Apoptose
Células Secretoras de Insulina/efeitos dos fármacos
Transdução de Sinais
/metabolismo
TOLL-LIKE RECEPTOR ABBREVIATIONS AS TOPIC/metabolismo
-Linhagem Celular Tumoral
/metabolismo
CASPASE ABATTOIRS/metabolismo
Fragmentação do DNA
Ativação Enzimática
Proteínas I-kappa B/metabolismo
Imunoprecipitação
Células Secretoras de Insulina/metabolismo
Proteínas Quinases JNK Ativadas por Mitógeno/metabolismo
Lipopeptídeos/farmacologia
/metabolismo
MYELOID DIFFERENTIATION FACTOR ACETATE KINASE/metabolismo
Palmitatos
Ligação Proteica
Fosfoproteínas/metabolismo
Poli(ADP-Ribose) Polimerases/metabolismo
Interferência de RNA
/genética
TOLL-LIKE RECEPTOR ABBREVIATIONS AS TOPIC/genética
/agonistas
TOLL-LIKE RECEPTOR TEMEFOS/agonistas
/genética
TOLL-LIKE RECEPTOR TEMEFOS/genética
/metabolismo
TOLL-LIKE RECEPTOR TEMEFOS/metabolismo
Limites: Animais
Ratos
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  9 / 11 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
ALVES, Sydney Hartz
Texto completo
Id: lil-624029
Autor: Mario, Débora Alves Nunes; Denardi, Laura Bedin; Bandeira, Laíssa Arévalo; Antunes, Milene Silva; Santurio, Janio Morais; Severo, Luiz Carlos; Alves, Sydney Hartz.
Título: The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates
Fonte: Mem. Inst. Oswaldo Cruz;107(3):433-436, May 2012. tab.
Idioma: en.
Resumo: The extensive use of azole antifungal agents has promoted the resistance of Candida spp to these drugs. Candida glabrata is a problematic yeast because it presents a high degree of primary or secondary resistance to fluconazole. In Brazil, C. glabrata has been less studied than other species. In this paper, we compared the activity of three major classes of antifungal agents (azoles, echinocandins and polyenes) against fluconazole-susceptible (FS) and fluconazole-resistant (FR) C. glabrata strains. Cross-resistance between fluconazole and voriconazole was remarkable. Among the antifungal agents, the echinocandins were the most effective against FS and FR C. glabrata and micafungin showed the lowest minimal inhibitory concentrations.
Descritores: Anfotericina B/farmacologia
Antifúngicos/farmacologia
Candida glabrata/efeitos dos fármacos
Equinocandinas/farmacologia
Fluconazol/farmacologia
Pirimidinas/farmacologia
Triazóis/farmacologia
-Candida glabrata/isolamento & purificação
Farmacorresistência Fúngica/efeitos dos fármacos
Lipopeptídeos/farmacologia
Testes de Sensibilidade Microbiana
Limites: Humanos
Tipo de Publ: Estudo Comparativo
Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  10 / 11 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-612151
Autor: Cortés L, Jorge A; Russi N, July A.
Título: Equinocandinas / Echinocandins
Fonte: Rev. chil. infectol;28(6):529-536, dic. 2011. ilus, tab.
Idioma: es.
Resumo: The echinocandins, caspofugin, micafungin, and anidulafungin, are lipopeptides that inhibit fungal growth by binding to β - (1.3) d glucan synthase. This enzyme is responsible for the formation of the peptidoglycan cell wall, and it is essential in fungi such as Candida spp, but less important in the case of Aspergillus and Fusarium species. We review the history, pharmacology and clinical trials that have showed clinical efficacy similar to amphotericin B for the management of fungal infections such as candidemia, invasive candidiasis and aspergillosis, even in cases refractory to initial treatment. These drugs have less toxicity and discontinuation is uncommonly required. Despite similar spectrum and tolerability, there are several pharmacological differences. Only a few clinical trials compare the clinical efficacy between them and their clinical application cannot be generalized. However, the echinocandins have demonstrated clinical efficacy in patients with invasive candidiasis and in others forms of systemic mycoses.

Las equinocandinas -caspofugina, micafungina y ani-dulafungina- son lipopéptidos que inhiben el crecimiento fúngico al unirse a la β-(1,3) d glucano sintetasa, enzima esencial para la síntesis en la pared celular de hongos como Candida spp, y menos importante en el caso de especies de Aspergillus y Fusarium. Se revisa la historia, farmacología y los diferentes ensayos clínicos que han evidenciado similar eficacia clínica a la de anfotericina B para el manejo de infecciones micóticas como candidemia, candidiasis invasora y aspergilosis, inclusive en casos refractarios al manejo inicial. Estos medicamentos tienen menor toxicidad y en pocos casos hay necesidad de retiro del tratamiento. Dado su espectro y tolerabilidad similar, su farmacología permite diferenciarlas. Se dispone de información limitada de estudios clínicos que las comparen entre ellas, limitando la extrapolación de la información a todo el grupo. Sin embargo, presentan eficacia clínica comprobada en pacientes con varias micosis invasoras.
Descritores: Antifúngicos/farmacologia
Aspergillus/efeitos dos fármacos
Candida/efeitos dos fármacos
Equinocandinas/farmacologia
Lipopeptídeos/farmacologia
-Aspergillus/classificação
Ensaios Clínicos como Assunto
Candida/classificação
Testes de Sensibilidade Microbiana
Limites: Humanos
Tipo de Publ: Research Support, Non-U.S. Gov't
Revisão
Responsável: BR1.1 - BIREME



página 1 de 2 ir para página        
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde